Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




TTMV-HPV DNA Biomarker Predicts Recurrence of Oropharynx Cancer

By LabMedica International staff writers
Posted on 03 Mar 2022

A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. Results also indicate that the biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance, allowing physicians to personalize treatment more quickly for patients whose cancer returns.


Despite generally favorable outcomes, up to 20% of patients with human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma (OPSCC) will experience recurrence within five years of curative-intent therapy; approximately half of recurrences present with distant disease.

Currently, recurrence is detected primarily through imaging and physical exams, but there is wide variability in the use and frequency of these surveillance methods. There are indications that a biomarker test may detect recurrent disease earlier than imaging or other standard methods of post-treatment surveillance, allowing physicians to personalize treatment more quickly for patients whose cancer returns.

Oncologists at the Dana-Farber Cancer Institute (Boston, MA, USA) and their colleagues demonstrated in large, multi-institutional study that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment. In a retrospective clinical case series included 1,076 consecutive patients across 124 USA sites who were > 3 months post therapy for HPV-driven OPSCC and who had one or more circulating cell-free tumor tissue modified HPV DNA (TTMV-HPV DNA) test (NavDx, Naveris Laboratories, Natick, MA, USA) between 2/6/2020 and 6/11/2021. TTMV-HPV DNA for HPV subtypes 16, 18, 31, 33, and 35 was analyzed with ultrasensitive digital droplet PCR. Test results were compared to the results of subsequent clinical evidence of OPSCC, using nasopharyngolaryngoscopy and/or radiologic (CT, MRI, or PET-CT) evaluations and/or tissue biopsy.

The investigators reported that circulating TTMV-HPV DNA was positive in 80/1,076 patients (7.4%, TTMV range: 7 - 123,148 fragments (frgs)/mL) tested after definitive therapy. At the first positive surveillance test, 21/80 (26.2%) patients had known recurrence while 59/80 (73.8%) had no other evidence of disease (NED) or indeterminate disease status. Clinical follow-up was available on all patients. Among the 59 positive tests without clinically known recurrence, 55 (93.2%, TTMV range: 8 - 23,296 frgs/mL) had confirmed recurrence identified with 52 HPV 16-driven, and 1 and 2 with HPV 31 or 35-driven OPSCC respectively. Two patients have clinically suspicious lesions with negative biopsies, one with a base of tongue ulcer and one with a pulmonary nodule (TTMV range: 9-67 frgs/mL) and two are currently clinically NED (TTMV range: 16-79 frgs/mL) with scheduled repeat TTMV and radiologic surveillance.

Glenn J. Hanna, MD, an Assistant Professor of Medicine and lead author of the study, said, “Most patients had no other evidence of disease or clinically indeterminate disease status at the time of their first positive biomarker test. Incorporating a test for TTMV-HPV DNA into routine post-treatment follow-up can enable physicians to detect recurrent cancers earlier and allow us to start recommended interventions more quickly to improve outcomes.”

The authors concluded that their findings demonstrated the clinical validity and utility of circulating TTMV-HPV DNA testing in daily clinical practice as an effective surveillance tool for identifying patients with active and occult recurrent HPV-driven OPSCC. To date the positive predictive value for recurrence or persistence of HPV-driven OPSCC is 95.0% (76/80), which may increase with additional follow-up of cases remaining in active surveillance. Notably, the presence of circulating TTMV-HPV DNA was the first indication of recurrence for 72.4% of cases. These data will help inform clinical and guideline-endorsed strategies concerning the inclusion of circulating TTMV HPV-DNA as a biomarker of molecularly detectable HPV-driven OPSCC in the setting of recurrence surveillance. The study was presented at the on February 24, 2022, at the 2022 Multidisciplinary Head and Neck Cancers Symposium held in Phoenix, AZ, USA.

Related Links:
Dana-Farber Cancer Institute 
Naveris Laboratories 


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Centrifuge
Hematocrit Centrifuge 7511M4
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.